Stock Fundamentals

Company Information

Company Name
UroGen Pharma Ltd
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: IL0011407140
CIK: 0001668243
CUSIP: M96088105
Currency: USD
Full Time Employees: 298
Phone: 646 768 9780
Fiscal Year End: December
IPO Date: May 04, 2017
Description:

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

Address:

400 Alexander Park Drive, Princeton, NJ, United States, 08540

Directors & Officers

Name Title Year Born
Ms. Elizabeth A. Barrett President, CEO & Director 1962
Mr. Jason Drew Smith J.D. General Counsel, Chief Compliance Officer & Corporate Secretary 1972
Dr. Mark P. Schoenberg M.D. Chief Medical Officer 1958
Mr. Christopher Degnan CPA Chief Financial Officer 1980
Mr. Vincent I. Perrone Senior Director of Investor Relations NA
Ms. Alison Hardgrove Senior Vice President of Human Resources NA
Dr. Marina Konorty Ph.D. Executive Vice President of Research & Development and Technical Operations NA
Mr. James Ottinger R.ph. Executive Vice President of Regulatory Affairs & Quality NA
Mr. Michael J. Louie M.D., M.P.H., M.Sc. Chief Development Officer NA
Mr. Timothy Simon Senior Vice President of Business Development & Portfolio Strategy NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 03, 2026 Jason Drew Smith N/A Sale 7.48K $19.69 $147.26K
Feb 03, 2026 Mark Schoenberg N/A Sale 7.37K $19.69 $145.17K
Nov 19, 2025 Mark Schoenberg N/A Sale 10.00K $25.00 $250.00K
Oct 08, 2025 Chris Degnan N/A Sale 2.20K $16.85 $37.12K
Sep 08, 2025 Jason Drew Smith N/A Sale 1.52K $19.11 $29.05K
Sep 08, 2025 Mark Schoenberg N/A Sale 871.00 $19.11 $16.64K
Aug 11, 2025 Mark Schoenberg N/A Sale 10.00K $17.69 $176.90K
Jul 28, 2025 Jason Drew Smith N/A Sale 7.52K $19.14 $143.97K
Jul 28, 2025 Mark Schoenberg N/A Sale 5.15K $19.14 $98.55K
Jun 09, 2025 Mark Schoenberg N/A Sale 5.16K $7.37 $38.04K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
RTW INVESTMENTS, LLC 4.54M Mar 31, 2026 9.33% $0.81 0.00%
BlackRock Inc 2.85M Mar 31, 2026 5.84% $0.00 9.40%
The Toronto-Dominion Bank 2.62M Mar 31, 2026 5.37% $0.07 0.00%
Morgan Stanley - Brokerage Accounts 2.56M Mar 31, 2026 5.25% $0.00 -0.11%
Kynam Capital Management, LP 2.25M Mar 31, 2026 4.61% $2.49 0.00%
Jefferies Financial Group Inc 2.20M Mar 31, 2026 4.51% $0.27 0.00%
Paradigm Biocapital Advisors LP 1.70M Mar 31, 2026 3.50% $0.63 -61.91%
SG Americas Securities, LLC 1.66M Mar 31, 2026 3.40% $0.03 20.34%
American Century Companies Inc 1.64M Mar 31, 2026 3.36% $0.02 20.51%
SILVERARC CAPITAL MANAGEMENT, LLC 1.50M Mar 31, 2026 3.09% $2.76 -13.56%
Opaleye Management Inc 1.43M Mar 31, 2026 2.94% $3.39 432.74%
Frontier Capital Management CO Inc 1.31M Mar 31, 2026 2.70% $0.24 68.13%
MENORA MIVTACHIM HOLDINGS LIMITED 1.15M Mar 31, 2026 2.37% $0.10 0.00%
D. E. Shaw & Co LP 1.02M Mar 31, 2026 2.10% $0.01 6.29%
MPM Oncology Impact Management LP 943.80K Mar 31, 2026 1.94% $1.31 0.26%
J. Goldman & Co LP 938.87K Mar 31, 2026 1.93% $0.49 82.91%
Orbimed Advisors, LLC 875.49K Mar 31, 2026 1.80% $0.31 0.00%
State Street Corp 874.18K Mar 31, 2026 1.79% $0.00 8.27%
Migdal Insurance & Financial Holdings Ltd 770.91K Mar 31, 2026 1.58% $0.12 0.00%
Soleus Capital Management, L.P. 727.00K Mar 31, 2026 1.49% $0.53 384.67%

Shares Statistics

Shares Outstanding: 48.72M
Shares Float: 43.17M
% Insiders: 364.60%
% Institutions: 10,058.80%
Short % Float: 14.49%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Russell 2000 ETF 958.89K 1.97% ▲ 0.93% May 29, 2026
2 American Century U.S. Small Cap Growth 874.98K 1.80% ▲ 33.99% Mar 31, 2026
3 American Century Small Cap Growth Inv 874.98K 1.80% ▲ 33.99% Mar 31, 2026
4 Biotech Growth Ord 536.83K 1.10% ▲ 0.00% Feb 28, 2026
5 Fidelity Small Cap Index 394.00K 0.81% ▲ 9.25% Mar 31, 2026
6 Xtrackers S&P 500 Swap ETF 1C 335.33K 0.69% ▲ 149.30% Dec 31, 2025
7 iShares Biotechnology ETF 285.53K 0.59% ▲ 1.95% May 29, 2026
8 iShares Russell 2000 Growth ETF 272.37K 0.56% ▼ 0.65% May 29, 2026
9 State St Russell Sm/Mid Cp® Indx SL Cl I 262.40K 0.54% ▲ 0.00% May 31, 2026
10 Russell 2000 Equity Index Fund B 222.92K 0.46% ▼ 6.57% Dec 31, 2025

Valuation Metrics

Enterprise Value: $1.50B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $1.45B
EBITDA: $-107.90M
PEG Ratio: $0.00
Book Value: $-2.55
Earnings/Share: $-2.74
Profit Margin: -94.83%
Operating Margin: -39.76%
ROA (TTM): -26.98%
ROE (TTM): -1,481.26%
Revenue (TTM): $140.49M
Revenue/Share (TTM): $2.88
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 151.60%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 4.01x -1.16x 1.53x -3.69x -0.90x
2024-12-31 6.01x -14.00x 1.03x -7.73x -1.29x
2023-12-31 5.42x -1.52x 1.37x -4.45x -1.65x
2022-12-31 5.39x -1.10x 1.66x -9.37x -1.29x
2021-12-31 5.11x 0.40x 0.93x -5.29x -0.03x
2020-12-31 5.39x 0.02x 0.21x -34.51x -0.01x
2019-12-31 7.63x 0.00x 0.11x -385.49x 0.00x
2018-12-31 7.59x 0.00x 0.13x N/A 0.00x
2017-12-31 10.59x 0.00x 0.09x N/A 0.00x
2016-12-31 7.03x 0.22x 0.29x N/A 3.57x
2015-12-31 8.55x 0.05x 0.12x N/A -0.07x
2014-12-31 4.81x 0.00x 0.20x N/A 0.00x
2013-12-31 6.50x 0.00x 0.15x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about URGN.US!